Arvinas (ARVN) Common Equity (2017 - 2026)
Arvinas (ARVN) posted quarterly Common Equity of $386.8 million for Q1 2026, down 41.4% year-over-year from $660.1 million in Q1 2025, and down 10.86% quarter-over-quarter from $433.9 million in Q4 2025.
Arvinas (ARVN) Common Equity (2017 - 2026) Analysis & Trends
Arvinas' Common Equity history runs 10 years deep, the most recent figure standing at $386.8 million for Q1 2026.
- In Q1 2026, Common Equity fell 41.4% year-over-year to $386.8 million; the TTM figure through Mar 2026 stood at $386.8 million (down 41.4% YoY), while the FY2025 annual figure was $433.9 million, down 22.75% from the prior year.
- Common Equity for Q1 2026 stood at $386.8 million, down from $433.9 million in the prior quarter.
- The five-year high for Common Equity was $723.3 million in Q1 2022, with the low at $386.8 million in Q1 2026.
- The 5-year median for Common Equity is $586.0 million (2024), against an average of $569.7 million.
- The sharpest annual moves came in 2024 and 2026: Common Equity advanced 29.47% in 2024, then tumbled 41.4% in 2026.
- Arvinas' Common Equity stood at $564.9 million in 2022, then increased by 16.83% to $660.0 million in 2023, then fell by 14.89% to $561.7 million in 2024, then declined by 22.75% to $433.9 million in 2025, then slipped by 10.86% to $386.8 million in 2026.
- Business Quant data shows ARVN's Common Equity at $386.8 million in Q1 2026, $433.9 million in Q4 2025, and $564.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 562.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 562.20 Mn |
| Mar 31, 2026 | 386.80 Mn |
| Dec 31, 2025 | 433.90 Mn |
| Sep 30, 2025 | 564.40 Mn |
| Jun 30, 2025 | 609.30 Mn |
| Mar 31, 2025 | 660.10 Mn |
| Dec 31, 2024 | 561.70 Mn |
| Sep 30, 2024 | 586.00 Mn |
| Jun 30, 2024 | 600.20 Mn |
| Mar 31, 2024 | 609.70 Mn |
| Dec 31, 2023 | 660.00 Mn |
| Sep 30, 2023 | 457.20 Mn |
| Jun 30, 2023 | 463.60 Mn |
| Mar 31, 2023 | 511.00 Mn |
| Dec 31, 2022 | 564.90 Mn |
| Sep 30, 2022 | 621.50 Mn |
| Jun 30, 2022 | 670.60 Mn |
| Mar 31, 2022 | 723.30 Mn |
| Dec 31, 2021 | 781.70 Mn |
| Sep 30, 2021 | 817.70 Mn |